{"file_path": "/Users/sz904/Desktop/11711/LTI_Neural_Navigator/data/2024-02-26/chunk_paper_txt/Yiming_Yang_Association_between_albumin-to-globulin_ratio_and_the_risk_of_overall_survival_in_advanced_non-small_cell_lung_cancer_patients_with_anlotinib_treatment:_a_retrospective_cohort_study_chunk_6.txt", "num_qa_pairs": 10, "qa_list": [{"question": " What is AGR and why is it relevant in the context of the study?", "answer": " AGR stands for albumin-to-globulin ratio and it may be a clinical indicator associated with overall survival (OS) for advanced non-small cell lung cancer (NSCLC) patients treated with anlotinib.", "ref_chunk": "the final manuscript. To our knowledge, we are the first to show that AGR may be a clinical indicator associated with OS for advanced NSCLC patients treated with anlotinib. Since AGR is a simple, inexpensive and easily available bio- marker, and is part of routinely administered laboratory tests, it is economically beneficial for its widespread clini- cal application. Despite the above-mentioned strengths, there are some limitations in our study. First, this study is a retrospective cohort study, and thus, it provides only weak evidence of associations between AGR and OS; it is hard to distinguish cause and effect. Second, the manifestations of possible selection bias, detection bias, and analysis bias might be confounded due to the nature of retrospective study. Third, as the absence of prior research in investigating the association between AGR and OS specifically in patients with ECOG PS score = 1 group, further investigations to understand the underlying mechanisms and determine if this relation- ship is consistent across different patient populations are Funding This work is funded by Xiamen Medical and Health Guidance Project (No. 3502Z20224ZD1085), grants from Shanghai science and technology innovation action plan (No. 21140902700), the National Natural Science Foundation of China (82170088), Natural Science Foundation of Fujian Province, China (2022J05330), and Major medical and health projects of Xiamen (No. 3502Z20204008). Data Availability The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Zhongshan hospital (Xiamen), Fudan university (B2022-067) and conducted in accordance with the principles of the Declaration of Helsinki. As it is a retrospective observational study, the ethics committee of Zhongshan hospital (Xiamen), Fudan university waived the requirement to obtain informed consent. Consent for publication Not applicable. Page 10 of 10 Competing interests The authors declare no competing interests. 12. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. AM J KIDNEY DIS. 1998;32(6 Suppl 4):118\u2013S125. Author details 1Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 2Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361000, Fujian, China 3Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China 4College of Computer and Data Science, Fuzhou University, Fuzhou 350108, Fujian, China 5Department of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 6Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China 13. Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuett- fort VM, Karakiewicz PI, Roupr\u00eat M, Enikeev D, et al. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. WORLD J UROL. 2021;39(9):3345\u201352. 14. Xie H, Zhang Q, Ruan G, Ge Y, Hu C, Song M, Song C, Zhang X, Zhang X, Li X et al. Evaluation and validation of the Prognostic Value of serum albumin to globulin ratio in patients with Cancer Cachexia: results from a large Multi- center collaboration. FRONT ONCOL 2021, 11. 15. Guo X, Shao J, Zhai B, Zou Q, Yan J, Gu H, Wang G. Relationship and prognos- tic significance between preoperative serum albumin to globulin ratio and CT features of non-small cell lung cancer. EUR J RADIOL. 2020;128:109039. 16. Suh B, Park S, Shin DW, Yun JM, Keam B, Yang HK, Ahn E, Lee H, Park JH, Cho B. Low albumin-to-globulin ratio associated with cancer incidence and mortal- ity in generally healthy adults. ANN ONCOL. 2014;25(11):2260\u20136. Received: 12 March 2023 / Accepted: 19 July 2023 17. Fitchett E, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, et al. Strengthening the reporting of Obser- vational Studies in Epidemiology for Newborn infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. LANCET INFECT DIS. 2016;16(10):e202\u201313. 18. Bozkaya Y, Erdem GU, Demirci NS, Yazici O, Ozdemir NY, Kostek O, Zengin N. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. CURR MED RES OPIN. 2019;35(2):275\u201382. References 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7\u201333. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. 3. Haseltine JM, Rimner A, Shepherd AF, Wu AJ, Gelblum DY, Shaverdian N, 2. 4. Gomez DR, Simone CN. Delivering safe and effective stereotactic body radia- tion therapy for patients with centrally located early stage non-small cell lung cancer. Chin Clin Oncol. 2020;9(3):39. Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. CANCER SCI. 2018;109(4):1207\u201319. 19. Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, Deng M. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135\u201348. 20. Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Shirabe K. Relationship between FDG uptake and Neutrophil/Lym- phocyte ratio in patients with invasive ductal breast Cancer. ANTICANCER RES. 2018;38(8):4927\u201331. 21. Liu Y, Yin Z, Lu P, Ma Y, Luo B, Xiang L, Zhang W, He Y, Liang X. Lung carcinoma cells secrete exosomal MALAT1 to inhibit dendritic cell phagocytosis, inflammatory response, Costimulatory Molecule expression and promote dendritic cell autophagy via AKT/mTOR pathway. Onco Targets Ther. 2020;13:10693\u2013705. 5. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with Advanced non\u2013small cell Lung Cancer. JAMA ONCOL. 2018;4(11):1569. Zhang H, Zhang B, Zhu K, Wu C, Gao L, Sun X, Liu C, Wang C. Preoperative albumin-to\u2010globulin ratio predicts survival in patients with non\u2010small\u2010cell lung cancer after surgery. J CELL PHYSIOL. 2019;234(3):2471\u20139. 6. 7. Gupta N, Sharma A, Sharma A. Emerging biomarkers"}, {"question": " What are the advantages of using AGR as a clinical indicator?", "answer": " AGR is simple, inexpensive, easily available, and part of routinely administered laboratory tests, making it economically beneficial for widespread clinical application.", "ref_chunk": "the final manuscript. To our knowledge, we are the first to show that AGR may be a clinical indicator associated with OS for advanced NSCLC patients treated with anlotinib. Since AGR is a simple, inexpensive and easily available bio- marker, and is part of routinely administered laboratory tests, it is economically beneficial for its widespread clini- cal application. Despite the above-mentioned strengths, there are some limitations in our study. First, this study is a retrospective cohort study, and thus, it provides only weak evidence of associations between AGR and OS; it is hard to distinguish cause and effect. Second, the manifestations of possible selection bias, detection bias, and analysis bias might be confounded due to the nature of retrospective study. Third, as the absence of prior research in investigating the association between AGR and OS specifically in patients with ECOG PS score = 1 group, further investigations to understand the underlying mechanisms and determine if this relation- ship is consistent across different patient populations are Funding This work is funded by Xiamen Medical and Health Guidance Project (No. 3502Z20224ZD1085), grants from Shanghai science and technology innovation action plan (No. 21140902700), the National Natural Science Foundation of China (82170088), Natural Science Foundation of Fujian Province, China (2022J05330), and Major medical and health projects of Xiamen (No. 3502Z20204008). Data Availability The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Zhongshan hospital (Xiamen), Fudan university (B2022-067) and conducted in accordance with the principles of the Declaration of Helsinki. As it is a retrospective observational study, the ethics committee of Zhongshan hospital (Xiamen), Fudan university waived the requirement to obtain informed consent. Consent for publication Not applicable. Page 10 of 10 Competing interests The authors declare no competing interests. 12. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. AM J KIDNEY DIS. 1998;32(6 Suppl 4):118\u2013S125. Author details 1Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 2Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361000, Fujian, China 3Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China 4College of Computer and Data Science, Fuzhou University, Fuzhou 350108, Fujian, China 5Department of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 6Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China 13. Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuett- fort VM, Karakiewicz PI, Roupr\u00eat M, Enikeev D, et al. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. WORLD J UROL. 2021;39(9):3345\u201352. 14. Xie H, Zhang Q, Ruan G, Ge Y, Hu C, Song M, Song C, Zhang X, Zhang X, Li X et al. Evaluation and validation of the Prognostic Value of serum albumin to globulin ratio in patients with Cancer Cachexia: results from a large Multi- center collaboration. FRONT ONCOL 2021, 11. 15. Guo X, Shao J, Zhai B, Zou Q, Yan J, Gu H, Wang G. Relationship and prognos- tic significance between preoperative serum albumin to globulin ratio and CT features of non-small cell lung cancer. EUR J RADIOL. 2020;128:109039. 16. Suh B, Park S, Shin DW, Yun JM, Keam B, Yang HK, Ahn E, Lee H, Park JH, Cho B. Low albumin-to-globulin ratio associated with cancer incidence and mortal- ity in generally healthy adults. ANN ONCOL. 2014;25(11):2260\u20136. Received: 12 March 2023 / Accepted: 19 July 2023 17. Fitchett E, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, et al. Strengthening the reporting of Obser- vational Studies in Epidemiology for Newborn infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. LANCET INFECT DIS. 2016;16(10):e202\u201313. 18. Bozkaya Y, Erdem GU, Demirci NS, Yazici O, Ozdemir NY, Kostek O, Zengin N. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. CURR MED RES OPIN. 2019;35(2):275\u201382. References 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7\u201333. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. 3. Haseltine JM, Rimner A, Shepherd AF, Wu AJ, Gelblum DY, Shaverdian N, 2. 4. Gomez DR, Simone CN. Delivering safe and effective stereotactic body radia- tion therapy for patients with centrally located early stage non-small cell lung cancer. Chin Clin Oncol. 2020;9(3):39. Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. CANCER SCI. 2018;109(4):1207\u201319. 19. Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, Deng M. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135\u201348. 20. Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Shirabe K. Relationship between FDG uptake and Neutrophil/Lym- phocyte ratio in patients with invasive ductal breast Cancer. ANTICANCER RES. 2018;38(8):4927\u201331. 21. Liu Y, Yin Z, Lu P, Ma Y, Luo B, Xiang L, Zhang W, He Y, Liang X. Lung carcinoma cells secrete exosomal MALAT1 to inhibit dendritic cell phagocytosis, inflammatory response, Costimulatory Molecule expression and promote dendritic cell autophagy via AKT/mTOR pathway. Onco Targets Ther. 2020;13:10693\u2013705. 5. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with Advanced non\u2013small cell Lung Cancer. JAMA ONCOL. 2018;4(11):1569. Zhang H, Zhang B, Zhu K, Wu C, Gao L, Sun X, Liu C, Wang C. Preoperative albumin-to\u2010globulin ratio predicts survival in patients with non\u2010small\u2010cell lung cancer after surgery. J CELL PHYSIOL. 2019;234(3):2471\u20139. 6. 7. Gupta N, Sharma A, Sharma A. Emerging biomarkers"}, {"question": " What are some limitations of the study mentioned in the text?", "answer": " The study is a retrospective cohort study, providing only weak evidence of associations between AGR and OS; it is hard to distinguish cause and effect. Possible biases like selection, detection, and analysis bias could confound the results. Additionally, there is a lack of prior research investigating the association between AGR and OS in patients with ECOG PS score = 1 group.", "ref_chunk": "the final manuscript. To our knowledge, we are the first to show that AGR may be a clinical indicator associated with OS for advanced NSCLC patients treated with anlotinib. Since AGR is a simple, inexpensive and easily available bio- marker, and is part of routinely administered laboratory tests, it is economically beneficial for its widespread clini- cal application. Despite the above-mentioned strengths, there are some limitations in our study. First, this study is a retrospective cohort study, and thus, it provides only weak evidence of associations between AGR and OS; it is hard to distinguish cause and effect. Second, the manifestations of possible selection bias, detection bias, and analysis bias might be confounded due to the nature of retrospective study. Third, as the absence of prior research in investigating the association between AGR and OS specifically in patients with ECOG PS score = 1 group, further investigations to understand the underlying mechanisms and determine if this relation- ship is consistent across different patient populations are Funding This work is funded by Xiamen Medical and Health Guidance Project (No. 3502Z20224ZD1085), grants from Shanghai science and technology innovation action plan (No. 21140902700), the National Natural Science Foundation of China (82170088), Natural Science Foundation of Fujian Province, China (2022J05330), and Major medical and health projects of Xiamen (No. 3502Z20204008). Data Availability The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Zhongshan hospital (Xiamen), Fudan university (B2022-067) and conducted in accordance with the principles of the Declaration of Helsinki. As it is a retrospective observational study, the ethics committee of Zhongshan hospital (Xiamen), Fudan university waived the requirement to obtain informed consent. Consent for publication Not applicable. Page 10 of 10 Competing interests The authors declare no competing interests. 12. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. AM J KIDNEY DIS. 1998;32(6 Suppl 4):118\u2013S125. Author details 1Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 2Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361000, Fujian, China 3Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China 4College of Computer and Data Science, Fuzhou University, Fuzhou 350108, Fujian, China 5Department of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 6Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China 13. Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuett- fort VM, Karakiewicz PI, Roupr\u00eat M, Enikeev D, et al. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. WORLD J UROL. 2021;39(9):3345\u201352. 14. Xie H, Zhang Q, Ruan G, Ge Y, Hu C, Song M, Song C, Zhang X, Zhang X, Li X et al. Evaluation and validation of the Prognostic Value of serum albumin to globulin ratio in patients with Cancer Cachexia: results from a large Multi- center collaboration. FRONT ONCOL 2021, 11. 15. Guo X, Shao J, Zhai B, Zou Q, Yan J, Gu H, Wang G. Relationship and prognos- tic significance between preoperative serum albumin to globulin ratio and CT features of non-small cell lung cancer. EUR J RADIOL. 2020;128:109039. 16. Suh B, Park S, Shin DW, Yun JM, Keam B, Yang HK, Ahn E, Lee H, Park JH, Cho B. Low albumin-to-globulin ratio associated with cancer incidence and mortal- ity in generally healthy adults. ANN ONCOL. 2014;25(11):2260\u20136. Received: 12 March 2023 / Accepted: 19 July 2023 17. Fitchett E, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, et al. Strengthening the reporting of Obser- vational Studies in Epidemiology for Newborn infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. LANCET INFECT DIS. 2016;16(10):e202\u201313. 18. Bozkaya Y, Erdem GU, Demirci NS, Yazici O, Ozdemir NY, Kostek O, Zengin N. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. CURR MED RES OPIN. 2019;35(2):275\u201382. References 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7\u201333. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. 3. Haseltine JM, Rimner A, Shepherd AF, Wu AJ, Gelblum DY, Shaverdian N, 2. 4. Gomez DR, Simone CN. Delivering safe and effective stereotactic body radia- tion therapy for patients with centrally located early stage non-small cell lung cancer. Chin Clin Oncol. 2020;9(3):39. Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. CANCER SCI. 2018;109(4):1207\u201319. 19. Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, Deng M. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135\u201348. 20. Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Shirabe K. Relationship between FDG uptake and Neutrophil/Lym- phocyte ratio in patients with invasive ductal breast Cancer. ANTICANCER RES. 2018;38(8):4927\u201331. 21. Liu Y, Yin Z, Lu P, Ma Y, Luo B, Xiang L, Zhang W, He Y, Liang X. Lung carcinoma cells secrete exosomal MALAT1 to inhibit dendritic cell phagocytosis, inflammatory response, Costimulatory Molecule expression and promote dendritic cell autophagy via AKT/mTOR pathway. Onco Targets Ther. 2020;13:10693\u2013705. 5. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with Advanced non\u2013small cell Lung Cancer. JAMA ONCOL. 2018;4(11):1569. Zhang H, Zhang B, Zhu K, Wu C, Gao L, Sun X, Liu C, Wang C. Preoperative albumin-to\u2010globulin ratio predicts survival in patients with non\u2010small\u2010cell lung cancer after surgery. J CELL PHYSIOL. 2019;234(3):2471\u20139. 6. 7. Gupta N, Sharma A, Sharma A. Emerging biomarkers"}, {"question": " What is the funding source for the work mentioned in the text?", "answer": " The work is funded by Xiamen Medical and Health Guidance Project, grants from Shanghai science and technology innovation action plan, the National Natural Science Foundation of China, Natural Science Foundation of Fujian Province, and Major medical and health projects of Xiamen.", "ref_chunk": "the final manuscript. To our knowledge, we are the first to show that AGR may be a clinical indicator associated with OS for advanced NSCLC patients treated with anlotinib. Since AGR is a simple, inexpensive and easily available bio- marker, and is part of routinely administered laboratory tests, it is economically beneficial for its widespread clini- cal application. Despite the above-mentioned strengths, there are some limitations in our study. First, this study is a retrospective cohort study, and thus, it provides only weak evidence of associations between AGR and OS; it is hard to distinguish cause and effect. Second, the manifestations of possible selection bias, detection bias, and analysis bias might be confounded due to the nature of retrospective study. Third, as the absence of prior research in investigating the association between AGR and OS specifically in patients with ECOG PS score = 1 group, further investigations to understand the underlying mechanisms and determine if this relation- ship is consistent across different patient populations are Funding This work is funded by Xiamen Medical and Health Guidance Project (No. 3502Z20224ZD1085), grants from Shanghai science and technology innovation action plan (No. 21140902700), the National Natural Science Foundation of China (82170088), Natural Science Foundation of Fujian Province, China (2022J05330), and Major medical and health projects of Xiamen (No. 3502Z20204008). Data Availability The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Zhongshan hospital (Xiamen), Fudan university (B2022-067) and conducted in accordance with the principles of the Declaration of Helsinki. As it is a retrospective observational study, the ethics committee of Zhongshan hospital (Xiamen), Fudan university waived the requirement to obtain informed consent. Consent for publication Not applicable. Page 10 of 10 Competing interests The authors declare no competing interests. 12. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. AM J KIDNEY DIS. 1998;32(6 Suppl 4):118\u2013S125. Author details 1Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 2Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361000, Fujian, China 3Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China 4College of Computer and Data Science, Fuzhou University, Fuzhou 350108, Fujian, China 5Department of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 6Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China 13. Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuett- fort VM, Karakiewicz PI, Roupr\u00eat M, Enikeev D, et al. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. WORLD J UROL. 2021;39(9):3345\u201352. 14. Xie H, Zhang Q, Ruan G, Ge Y, Hu C, Song M, Song C, Zhang X, Zhang X, Li X et al. Evaluation and validation of the Prognostic Value of serum albumin to globulin ratio in patients with Cancer Cachexia: results from a large Multi- center collaboration. FRONT ONCOL 2021, 11. 15. Guo X, Shao J, Zhai B, Zou Q, Yan J, Gu H, Wang G. Relationship and prognos- tic significance between preoperative serum albumin to globulin ratio and CT features of non-small cell lung cancer. EUR J RADIOL. 2020;128:109039. 16. Suh B, Park S, Shin DW, Yun JM, Keam B, Yang HK, Ahn E, Lee H, Park JH, Cho B. Low albumin-to-globulin ratio associated with cancer incidence and mortal- ity in generally healthy adults. ANN ONCOL. 2014;25(11):2260\u20136. Received: 12 March 2023 / Accepted: 19 July 2023 17. Fitchett E, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, et al. Strengthening the reporting of Obser- vational Studies in Epidemiology for Newborn infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. LANCET INFECT DIS. 2016;16(10):e202\u201313. 18. Bozkaya Y, Erdem GU, Demirci NS, Yazici O, Ozdemir NY, Kostek O, Zengin N. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. CURR MED RES OPIN. 2019;35(2):275\u201382. References 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7\u201333. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. 3. Haseltine JM, Rimner A, Shepherd AF, Wu AJ, Gelblum DY, Shaverdian N, 2. 4. Gomez DR, Simone CN. Delivering safe and effective stereotactic body radia- tion therapy for patients with centrally located early stage non-small cell lung cancer. Chin Clin Oncol. 2020;9(3):39. Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. CANCER SCI. 2018;109(4):1207\u201319. 19. Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, Deng M. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135\u201348. 20. Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Shirabe K. Relationship between FDG uptake and Neutrophil/Lym- phocyte ratio in patients with invasive ductal breast Cancer. ANTICANCER RES. 2018;38(8):4927\u201331. 21. Liu Y, Yin Z, Lu P, Ma Y, Luo B, Xiang L, Zhang W, He Y, Liang X. Lung carcinoma cells secrete exosomal MALAT1 to inhibit dendritic cell phagocytosis, inflammatory response, Costimulatory Molecule expression and promote dendritic cell autophagy via AKT/mTOR pathway. Onco Targets Ther. 2020;13:10693\u2013705. 5. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with Advanced non\u2013small cell Lung Cancer. JAMA ONCOL. 2018;4(11):1569. Zhang H, Zhang B, Zhu K, Wu C, Gao L, Sun X, Liu C, Wang C. Preoperative albumin-to\u2010globulin ratio predicts survival in patients with non\u2010small\u2010cell lung cancer after surgery. J CELL PHYSIOL. 2019;234(3):2471\u20139. 6. 7. Gupta N, Sharma A, Sharma A. Emerging biomarkers"}, {"question": " How are the datasets used in the study made available?", "answer": " The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.", "ref_chunk": "the final manuscript. To our knowledge, we are the first to show that AGR may be a clinical indicator associated with OS for advanced NSCLC patients treated with anlotinib. Since AGR is a simple, inexpensive and easily available bio- marker, and is part of routinely administered laboratory tests, it is economically beneficial for its widespread clini- cal application. Despite the above-mentioned strengths, there are some limitations in our study. First, this study is a retrospective cohort study, and thus, it provides only weak evidence of associations between AGR and OS; it is hard to distinguish cause and effect. Second, the manifestations of possible selection bias, detection bias, and analysis bias might be confounded due to the nature of retrospective study. Third, as the absence of prior research in investigating the association between AGR and OS specifically in patients with ECOG PS score = 1 group, further investigations to understand the underlying mechanisms and determine if this relation- ship is consistent across different patient populations are Funding This work is funded by Xiamen Medical and Health Guidance Project (No. 3502Z20224ZD1085), grants from Shanghai science and technology innovation action plan (No. 21140902700), the National Natural Science Foundation of China (82170088), Natural Science Foundation of Fujian Province, China (2022J05330), and Major medical and health projects of Xiamen (No. 3502Z20204008). Data Availability The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Zhongshan hospital (Xiamen), Fudan university (B2022-067) and conducted in accordance with the principles of the Declaration of Helsinki. As it is a retrospective observational study, the ethics committee of Zhongshan hospital (Xiamen), Fudan university waived the requirement to obtain informed consent. Consent for publication Not applicable. Page 10 of 10 Competing interests The authors declare no competing interests. 12. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. AM J KIDNEY DIS. 1998;32(6 Suppl 4):118\u2013S125. Author details 1Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 2Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361000, Fujian, China 3Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China 4College of Computer and Data Science, Fuzhou University, Fuzhou 350108, Fujian, China 5Department of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 6Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China 13. Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuett- fort VM, Karakiewicz PI, Roupr\u00eat M, Enikeev D, et al. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. WORLD J UROL. 2021;39(9):3345\u201352. 14. Xie H, Zhang Q, Ruan G, Ge Y, Hu C, Song M, Song C, Zhang X, Zhang X, Li X et al. Evaluation and validation of the Prognostic Value of serum albumin to globulin ratio in patients with Cancer Cachexia: results from a large Multi- center collaboration. FRONT ONCOL 2021, 11. 15. Guo X, Shao J, Zhai B, Zou Q, Yan J, Gu H, Wang G. Relationship and prognos- tic significance between preoperative serum albumin to globulin ratio and CT features of non-small cell lung cancer. EUR J RADIOL. 2020;128:109039. 16. Suh B, Park S, Shin DW, Yun JM, Keam B, Yang HK, Ahn E, Lee H, Park JH, Cho B. Low albumin-to-globulin ratio associated with cancer incidence and mortal- ity in generally healthy adults. ANN ONCOL. 2014;25(11):2260\u20136. Received: 12 March 2023 / Accepted: 19 July 2023 17. Fitchett E, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, et al. Strengthening the reporting of Obser- vational Studies in Epidemiology for Newborn infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. LANCET INFECT DIS. 2016;16(10):e202\u201313. 18. Bozkaya Y, Erdem GU, Demirci NS, Yazici O, Ozdemir NY, Kostek O, Zengin N. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. CURR MED RES OPIN. 2019;35(2):275\u201382. References 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7\u201333. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. 3. Haseltine JM, Rimner A, Shepherd AF, Wu AJ, Gelblum DY, Shaverdian N, 2. 4. Gomez DR, Simone CN. Delivering safe and effective stereotactic body radia- tion therapy for patients with centrally located early stage non-small cell lung cancer. Chin Clin Oncol. 2020;9(3):39. Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. CANCER SCI. 2018;109(4):1207\u201319. 19. Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, Deng M. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135\u201348. 20. Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Shirabe K. Relationship between FDG uptake and Neutrophil/Lym- phocyte ratio in patients with invasive ductal breast Cancer. ANTICANCER RES. 2018;38(8):4927\u201331. 21. Liu Y, Yin Z, Lu P, Ma Y, Luo B, Xiang L, Zhang W, He Y, Liang X. Lung carcinoma cells secrete exosomal MALAT1 to inhibit dendritic cell phagocytosis, inflammatory response, Costimulatory Molecule expression and promote dendritic cell autophagy via AKT/mTOR pathway. Onco Targets Ther. 2020;13:10693\u2013705. 5. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with Advanced non\u2013small cell Lung Cancer. JAMA ONCOL. 2018;4(11):1569. Zhang H, Zhang B, Zhu K, Wu C, Gao L, Sun X, Liu C, Wang C. Preoperative albumin-to\u2010globulin ratio predicts survival in patients with non\u2010small\u2010cell lung cancer after surgery. J CELL PHYSIOL. 2019;234(3):2471\u20139. 6. 7. Gupta N, Sharma A, Sharma A. Emerging biomarkers"}, {"question": " What approvals were obtained for conducting the study?", "answer": " The study was approved by the Ethics Committee of Zhongshan Hospital (Xiamen), Fudan University and conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was waived due to the retrospective nature of the study.", "ref_chunk": "the final manuscript. To our knowledge, we are the first to show that AGR may be a clinical indicator associated with OS for advanced NSCLC patients treated with anlotinib. Since AGR is a simple, inexpensive and easily available bio- marker, and is part of routinely administered laboratory tests, it is economically beneficial for its widespread clini- cal application. Despite the above-mentioned strengths, there are some limitations in our study. First, this study is a retrospective cohort study, and thus, it provides only weak evidence of associations between AGR and OS; it is hard to distinguish cause and effect. Second, the manifestations of possible selection bias, detection bias, and analysis bias might be confounded due to the nature of retrospective study. Third, as the absence of prior research in investigating the association between AGR and OS specifically in patients with ECOG PS score = 1 group, further investigations to understand the underlying mechanisms and determine if this relation- ship is consistent across different patient populations are Funding This work is funded by Xiamen Medical and Health Guidance Project (No. 3502Z20224ZD1085), grants from Shanghai science and technology innovation action plan (No. 21140902700), the National Natural Science Foundation of China (82170088), Natural Science Foundation of Fujian Province, China (2022J05330), and Major medical and health projects of Xiamen (No. 3502Z20204008). Data Availability The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Zhongshan hospital (Xiamen), Fudan university (B2022-067) and conducted in accordance with the principles of the Declaration of Helsinki. As it is a retrospective observational study, the ethics committee of Zhongshan hospital (Xiamen), Fudan university waived the requirement to obtain informed consent. Consent for publication Not applicable. Page 10 of 10 Competing interests The authors declare no competing interests. 12. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. AM J KIDNEY DIS. 1998;32(6 Suppl 4):118\u2013S125. Author details 1Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 2Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361000, Fujian, China 3Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China 4College of Computer and Data Science, Fuzhou University, Fuzhou 350108, Fujian, China 5Department of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 6Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China 13. Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuett- fort VM, Karakiewicz PI, Roupr\u00eat M, Enikeev D, et al. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. WORLD J UROL. 2021;39(9):3345\u201352. 14. Xie H, Zhang Q, Ruan G, Ge Y, Hu C, Song M, Song C, Zhang X, Zhang X, Li X et al. Evaluation and validation of the Prognostic Value of serum albumin to globulin ratio in patients with Cancer Cachexia: results from a large Multi- center collaboration. FRONT ONCOL 2021, 11. 15. Guo X, Shao J, Zhai B, Zou Q, Yan J, Gu H, Wang G. Relationship and prognos- tic significance between preoperative serum albumin to globulin ratio and CT features of non-small cell lung cancer. EUR J RADIOL. 2020;128:109039. 16. Suh B, Park S, Shin DW, Yun JM, Keam B, Yang HK, Ahn E, Lee H, Park JH, Cho B. Low albumin-to-globulin ratio associated with cancer incidence and mortal- ity in generally healthy adults. ANN ONCOL. 2014;25(11):2260\u20136. Received: 12 March 2023 / Accepted: 19 July 2023 17. Fitchett E, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, et al. Strengthening the reporting of Obser- vational Studies in Epidemiology for Newborn infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. LANCET INFECT DIS. 2016;16(10):e202\u201313. 18. Bozkaya Y, Erdem GU, Demirci NS, Yazici O, Ozdemir NY, Kostek O, Zengin N. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. CURR MED RES OPIN. 2019;35(2):275\u201382. References 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7\u201333. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. 3. Haseltine JM, Rimner A, Shepherd AF, Wu AJ, Gelblum DY, Shaverdian N, 2. 4. Gomez DR, Simone CN. Delivering safe and effective stereotactic body radia- tion therapy for patients with centrally located early stage non-small cell lung cancer. Chin Clin Oncol. 2020;9(3):39. Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. CANCER SCI. 2018;109(4):1207\u201319. 19. Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, Deng M. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135\u201348. 20. Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Shirabe K. Relationship between FDG uptake and Neutrophil/Lym- phocyte ratio in patients with invasive ductal breast Cancer. ANTICANCER RES. 2018;38(8):4927\u201331. 21. Liu Y, Yin Z, Lu P, Ma Y, Luo B, Xiang L, Zhang W, He Y, Liang X. Lung carcinoma cells secrete exosomal MALAT1 to inhibit dendritic cell phagocytosis, inflammatory response, Costimulatory Molecule expression and promote dendritic cell autophagy via AKT/mTOR pathway. Onco Targets Ther. 2020;13:10693\u2013705. 5. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with Advanced non\u2013small cell Lung Cancer. JAMA ONCOL. 2018;4(11):1569. Zhang H, Zhang B, Zhu K, Wu C, Gao L, Sun X, Liu C, Wang C. Preoperative albumin-to\u2010globulin ratio predicts survival in patients with non\u2010small\u2010cell lung cancer after surgery. J CELL PHYSIOL. 2019;234(3):2471\u20139. 6. 7. Gupta N, Sharma A, Sharma A. Emerging biomarkers"}, {"question": " What is the significance of the Prognostic Value of serum albumin to globulin ratio in patients with Cancer Cachexia study?", "answer": " The study evaluates and validates the prognostic value of the serum albumin to globulin ratio in patients with Cancer Cachexia through a large multi-center collaboration.", "ref_chunk": "the final manuscript. To our knowledge, we are the first to show that AGR may be a clinical indicator associated with OS for advanced NSCLC patients treated with anlotinib. Since AGR is a simple, inexpensive and easily available bio- marker, and is part of routinely administered laboratory tests, it is economically beneficial for its widespread clini- cal application. Despite the above-mentioned strengths, there are some limitations in our study. First, this study is a retrospective cohort study, and thus, it provides only weak evidence of associations between AGR and OS; it is hard to distinguish cause and effect. Second, the manifestations of possible selection bias, detection bias, and analysis bias might be confounded due to the nature of retrospective study. Third, as the absence of prior research in investigating the association between AGR and OS specifically in patients with ECOG PS score = 1 group, further investigations to understand the underlying mechanisms and determine if this relation- ship is consistent across different patient populations are Funding This work is funded by Xiamen Medical and Health Guidance Project (No. 3502Z20224ZD1085), grants from Shanghai science and technology innovation action plan (No. 21140902700), the National Natural Science Foundation of China (82170088), Natural Science Foundation of Fujian Province, China (2022J05330), and Major medical and health projects of Xiamen (No. 3502Z20204008). Data Availability The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Zhongshan hospital (Xiamen), Fudan university (B2022-067) and conducted in accordance with the principles of the Declaration of Helsinki. As it is a retrospective observational study, the ethics committee of Zhongshan hospital (Xiamen), Fudan university waived the requirement to obtain informed consent. Consent for publication Not applicable. Page 10 of 10 Competing interests The authors declare no competing interests. 12. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. AM J KIDNEY DIS. 1998;32(6 Suppl 4):118\u2013S125. Author details 1Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 2Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361000, Fujian, China 3Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China 4College of Computer and Data Science, Fuzhou University, Fuzhou 350108, Fujian, China 5Department of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 6Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China 13. Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuett- fort VM, Karakiewicz PI, Roupr\u00eat M, Enikeev D, et al. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. WORLD J UROL. 2021;39(9):3345\u201352. 14. Xie H, Zhang Q, Ruan G, Ge Y, Hu C, Song M, Song C, Zhang X, Zhang X, Li X et al. Evaluation and validation of the Prognostic Value of serum albumin to globulin ratio in patients with Cancer Cachexia: results from a large Multi- center collaboration. FRONT ONCOL 2021, 11. 15. Guo X, Shao J, Zhai B, Zou Q, Yan J, Gu H, Wang G. Relationship and prognos- tic significance between preoperative serum albumin to globulin ratio and CT features of non-small cell lung cancer. EUR J RADIOL. 2020;128:109039. 16. Suh B, Park S, Shin DW, Yun JM, Keam B, Yang HK, Ahn E, Lee H, Park JH, Cho B. Low albumin-to-globulin ratio associated with cancer incidence and mortal- ity in generally healthy adults. ANN ONCOL. 2014;25(11):2260\u20136. Received: 12 March 2023 / Accepted: 19 July 2023 17. Fitchett E, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, et al. Strengthening the reporting of Obser- vational Studies in Epidemiology for Newborn infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. LANCET INFECT DIS. 2016;16(10):e202\u201313. 18. Bozkaya Y, Erdem GU, Demirci NS, Yazici O, Ozdemir NY, Kostek O, Zengin N. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. CURR MED RES OPIN. 2019;35(2):275\u201382. References 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7\u201333. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. 3. Haseltine JM, Rimner A, Shepherd AF, Wu AJ, Gelblum DY, Shaverdian N, 2. 4. Gomez DR, Simone CN. Delivering safe and effective stereotactic body radia- tion therapy for patients with centrally located early stage non-small cell lung cancer. Chin Clin Oncol. 2020;9(3):39. Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. CANCER SCI. 2018;109(4):1207\u201319. 19. Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, Deng M. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135\u201348. 20. Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Shirabe K. Relationship between FDG uptake and Neutrophil/Lym- phocyte ratio in patients with invasive ductal breast Cancer. ANTICANCER RES. 2018;38(8):4927\u201331. 21. Liu Y, Yin Z, Lu P, Ma Y, Luo B, Xiang L, Zhang W, He Y, Liang X. Lung carcinoma cells secrete exosomal MALAT1 to inhibit dendritic cell phagocytosis, inflammatory response, Costimulatory Molecule expression and promote dendritic cell autophagy via AKT/mTOR pathway. Onco Targets Ther. 2020;13:10693\u2013705. 5. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with Advanced non\u2013small cell Lung Cancer. JAMA ONCOL. 2018;4(11):1569. Zhang H, Zhang B, Zhu K, Wu C, Gao L, Sun X, Liu C, Wang C. Preoperative albumin-to\u2010globulin ratio predicts survival in patients with non\u2010small\u2010cell lung cancer after surgery. J CELL PHYSIOL. 2019;234(3):2471\u20139. 6. 7. Gupta N, Sharma A, Sharma A. Emerging biomarkers"}, {"question": " What is the relationship between the preoperative serum albumin to globulin ratio and CT features of non-small cell lung cancer?", "answer": " A low albumin-to-globulin ratio is associated with cancer incidence and mortality in generally healthy adults.", "ref_chunk": "the final manuscript. To our knowledge, we are the first to show that AGR may be a clinical indicator associated with OS for advanced NSCLC patients treated with anlotinib. Since AGR is a simple, inexpensive and easily available bio- marker, and is part of routinely administered laboratory tests, it is economically beneficial for its widespread clini- cal application. Despite the above-mentioned strengths, there are some limitations in our study. First, this study is a retrospective cohort study, and thus, it provides only weak evidence of associations between AGR and OS; it is hard to distinguish cause and effect. Second, the manifestations of possible selection bias, detection bias, and analysis bias might be confounded due to the nature of retrospective study. Third, as the absence of prior research in investigating the association between AGR and OS specifically in patients with ECOG PS score = 1 group, further investigations to understand the underlying mechanisms and determine if this relation- ship is consistent across different patient populations are Funding This work is funded by Xiamen Medical and Health Guidance Project (No. 3502Z20224ZD1085), grants from Shanghai science and technology innovation action plan (No. 21140902700), the National Natural Science Foundation of China (82170088), Natural Science Foundation of Fujian Province, China (2022J05330), and Major medical and health projects of Xiamen (No. 3502Z20204008). Data Availability The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Zhongshan hospital (Xiamen), Fudan university (B2022-067) and conducted in accordance with the principles of the Declaration of Helsinki. As it is a retrospective observational study, the ethics committee of Zhongshan hospital (Xiamen), Fudan university waived the requirement to obtain informed consent. Consent for publication Not applicable. Page 10 of 10 Competing interests The authors declare no competing interests. 12. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. AM J KIDNEY DIS. 1998;32(6 Suppl 4):118\u2013S125. Author details 1Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 2Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361000, Fujian, China 3Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China 4College of Computer and Data Science, Fuzhou University, Fuzhou 350108, Fujian, China 5Department of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 6Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China 13. Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuett- fort VM, Karakiewicz PI, Roupr\u00eat M, Enikeev D, et al. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. WORLD J UROL. 2021;39(9):3345\u201352. 14. Xie H, Zhang Q, Ruan G, Ge Y, Hu C, Song M, Song C, Zhang X, Zhang X, Li X et al. Evaluation and validation of the Prognostic Value of serum albumin to globulin ratio in patients with Cancer Cachexia: results from a large Multi- center collaboration. FRONT ONCOL 2021, 11. 15. Guo X, Shao J, Zhai B, Zou Q, Yan J, Gu H, Wang G. Relationship and prognos- tic significance between preoperative serum albumin to globulin ratio and CT features of non-small cell lung cancer. EUR J RADIOL. 2020;128:109039. 16. Suh B, Park S, Shin DW, Yun JM, Keam B, Yang HK, Ahn E, Lee H, Park JH, Cho B. Low albumin-to-globulin ratio associated with cancer incidence and mortal- ity in generally healthy adults. ANN ONCOL. 2014;25(11):2260\u20136. Received: 12 March 2023 / Accepted: 19 July 2023 17. Fitchett E, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, et al. Strengthening the reporting of Obser- vational Studies in Epidemiology for Newborn infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. LANCET INFECT DIS. 2016;16(10):e202\u201313. 18. Bozkaya Y, Erdem GU, Demirci NS, Yazici O, Ozdemir NY, Kostek O, Zengin N. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. CURR MED RES OPIN. 2019;35(2):275\u201382. References 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7\u201333. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. 3. Haseltine JM, Rimner A, Shepherd AF, Wu AJ, Gelblum DY, Shaverdian N, 2. 4. Gomez DR, Simone CN. Delivering safe and effective stereotactic body radia- tion therapy for patients with centrally located early stage non-small cell lung cancer. Chin Clin Oncol. 2020;9(3):39. Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. CANCER SCI. 2018;109(4):1207\u201319. 19. Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, Deng M. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135\u201348. 20. Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Shirabe K. Relationship between FDG uptake and Neutrophil/Lym- phocyte ratio in patients with invasive ductal breast Cancer. ANTICANCER RES. 2018;38(8):4927\u201331. 21. Liu Y, Yin Z, Lu P, Ma Y, Luo B, Xiang L, Zhang W, He Y, Liang X. Lung carcinoma cells secrete exosomal MALAT1 to inhibit dendritic cell phagocytosis, inflammatory response, Costimulatory Molecule expression and promote dendritic cell autophagy via AKT/mTOR pathway. Onco Targets Ther. 2020;13:10693\u2013705. 5. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with Advanced non\u2013small cell Lung Cancer. JAMA ONCOL. 2018;4(11):1569. Zhang H, Zhang B, Zhu K, Wu C, Gao L, Sun X, Liu C, Wang C. Preoperative albumin-to\u2010globulin ratio predicts survival in patients with non\u2010small\u2010cell lung cancer after surgery. J CELL PHYSIOL. 2019;234(3):2471\u20139. 6. 7. Gupta N, Sharma A, Sharma A. Emerging biomarkers"}, {"question": " What is the Strengthening the reporting of Observational Studies in Epidemiology for Newborn infection (STROBE-NI) extension aimed at?", "answer": " The STROBE-NI extension aims to strengthen the reporting of observational studies in epidemiology for newborn infection research.", "ref_chunk": "the final manuscript. To our knowledge, we are the first to show that AGR may be a clinical indicator associated with OS for advanced NSCLC patients treated with anlotinib. Since AGR is a simple, inexpensive and easily available bio- marker, and is part of routinely administered laboratory tests, it is economically beneficial for its widespread clini- cal application. Despite the above-mentioned strengths, there are some limitations in our study. First, this study is a retrospective cohort study, and thus, it provides only weak evidence of associations between AGR and OS; it is hard to distinguish cause and effect. Second, the manifestations of possible selection bias, detection bias, and analysis bias might be confounded due to the nature of retrospective study. Third, as the absence of prior research in investigating the association between AGR and OS specifically in patients with ECOG PS score = 1 group, further investigations to understand the underlying mechanisms and determine if this relation- ship is consistent across different patient populations are Funding This work is funded by Xiamen Medical and Health Guidance Project (No. 3502Z20224ZD1085), grants from Shanghai science and technology innovation action plan (No. 21140902700), the National Natural Science Foundation of China (82170088), Natural Science Foundation of Fujian Province, China (2022J05330), and Major medical and health projects of Xiamen (No. 3502Z20204008). Data Availability The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Zhongshan hospital (Xiamen), Fudan university (B2022-067) and conducted in accordance with the principles of the Declaration of Helsinki. As it is a retrospective observational study, the ethics committee of Zhongshan hospital (Xiamen), Fudan university waived the requirement to obtain informed consent. Consent for publication Not applicable. Page 10 of 10 Competing interests The authors declare no competing interests. 12. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. AM J KIDNEY DIS. 1998;32(6 Suppl 4):118\u2013S125. Author details 1Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 2Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361000, Fujian, China 3Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China 4College of Computer and Data Science, Fuzhou University, Fuzhou 350108, Fujian, China 5Department of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 6Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China 13. Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuett- fort VM, Karakiewicz PI, Roupr\u00eat M, Enikeev D, et al. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. WORLD J UROL. 2021;39(9):3345\u201352. 14. Xie H, Zhang Q, Ruan G, Ge Y, Hu C, Song M, Song C, Zhang X, Zhang X, Li X et al. Evaluation and validation of the Prognostic Value of serum albumin to globulin ratio in patients with Cancer Cachexia: results from a large Multi- center collaboration. FRONT ONCOL 2021, 11. 15. Guo X, Shao J, Zhai B, Zou Q, Yan J, Gu H, Wang G. Relationship and prognos- tic significance between preoperative serum albumin to globulin ratio and CT features of non-small cell lung cancer. EUR J RADIOL. 2020;128:109039. 16. Suh B, Park S, Shin DW, Yun JM, Keam B, Yang HK, Ahn E, Lee H, Park JH, Cho B. Low albumin-to-globulin ratio associated with cancer incidence and mortal- ity in generally healthy adults. ANN ONCOL. 2014;25(11):2260\u20136. Received: 12 March 2023 / Accepted: 19 July 2023 17. Fitchett E, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, et al. Strengthening the reporting of Obser- vational Studies in Epidemiology for Newborn infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. LANCET INFECT DIS. 2016;16(10):e202\u201313. 18. Bozkaya Y, Erdem GU, Demirci NS, Yazici O, Ozdemir NY, Kostek O, Zengin N. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. CURR MED RES OPIN. 2019;35(2):275\u201382. References 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7\u201333. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. 3. Haseltine JM, Rimner A, Shepherd AF, Wu AJ, Gelblum DY, Shaverdian N, 2. 4. Gomez DR, Simone CN. Delivering safe and effective stereotactic body radia- tion therapy for patients with centrally located early stage non-small cell lung cancer. Chin Clin Oncol. 2020;9(3):39. Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. CANCER SCI. 2018;109(4):1207\u201319. 19. Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, Deng M. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135\u201348. 20. Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Shirabe K. Relationship between FDG uptake and Neutrophil/Lym- phocyte ratio in patients with invasive ductal breast Cancer. ANTICANCER RES. 2018;38(8):4927\u201331. 21. Liu Y, Yin Z, Lu P, Ma Y, Luo B, Xiang L, Zhang W, He Y, Liang X. Lung carcinoma cells secrete exosomal MALAT1 to inhibit dendritic cell phagocytosis, inflammatory response, Costimulatory Molecule expression and promote dendritic cell autophagy via AKT/mTOR pathway. Onco Targets Ther. 2020;13:10693\u2013705. 5. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with Advanced non\u2013small cell Lung Cancer. JAMA ONCOL. 2018;4(11):1569. Zhang H, Zhang B, Zhu K, Wu C, Gao L, Sun X, Liu C, Wang C. Preoperative albumin-to\u2010globulin ratio predicts survival in patients with non\u2010small\u2010cell lung cancer after surgery. J CELL PHYSIOL. 2019;234(3):2471\u20139. 6. 7. Gupta N, Sharma A, Sharma A. Emerging biomarkers"}, {"question": " What is the prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients?", "answer": " The albumin to globulin ratio has prognostic importance in metastatic gastric cancer patients.", "ref_chunk": "the final manuscript. To our knowledge, we are the first to show that AGR may be a clinical indicator associated with OS for advanced NSCLC patients treated with anlotinib. Since AGR is a simple, inexpensive and easily available bio- marker, and is part of routinely administered laboratory tests, it is economically beneficial for its widespread clini- cal application. Despite the above-mentioned strengths, there are some limitations in our study. First, this study is a retrospective cohort study, and thus, it provides only weak evidence of associations between AGR and OS; it is hard to distinguish cause and effect. Second, the manifestations of possible selection bias, detection bias, and analysis bias might be confounded due to the nature of retrospective study. Third, as the absence of prior research in investigating the association between AGR and OS specifically in patients with ECOG PS score = 1 group, further investigations to understand the underlying mechanisms and determine if this relation- ship is consistent across different patient populations are Funding This work is funded by Xiamen Medical and Health Guidance Project (No. 3502Z20224ZD1085), grants from Shanghai science and technology innovation action plan (No. 21140902700), the National Natural Science Foundation of China (82170088), Natural Science Foundation of Fujian Province, China (2022J05330), and Major medical and health projects of Xiamen (No. 3502Z20204008). Data Availability The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Zhongshan hospital (Xiamen), Fudan university (B2022-067) and conducted in accordance with the principles of the Declaration of Helsinki. As it is a retrospective observational study, the ethics committee of Zhongshan hospital (Xiamen), Fudan university waived the requirement to obtain informed consent. Consent for publication Not applicable. Page 10 of 10 Competing interests The authors declare no competing interests. 12. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. AM J KIDNEY DIS. 1998;32(6 Suppl 4):118\u2013S125. Author details 1Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 2Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361000, Fujian, China 3Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China 4College of Computer and Data Science, Fuzhou University, Fuzhou 350108, Fujian, China 5Department of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 6Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China 13. Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuett- fort VM, Karakiewicz PI, Roupr\u00eat M, Enikeev D, et al. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. WORLD J UROL. 2021;39(9):3345\u201352. 14. Xie H, Zhang Q, Ruan G, Ge Y, Hu C, Song M, Song C, Zhang X, Zhang X, Li X et al. Evaluation and validation of the Prognostic Value of serum albumin to globulin ratio in patients with Cancer Cachexia: results from a large Multi- center collaboration. FRONT ONCOL 2021, 11. 15. Guo X, Shao J, Zhai B, Zou Q, Yan J, Gu H, Wang G. Relationship and prognos- tic significance between preoperative serum albumin to globulin ratio and CT features of non-small cell lung cancer. EUR J RADIOL. 2020;128:109039. 16. Suh B, Park S, Shin DW, Yun JM, Keam B, Yang HK, Ahn E, Lee H, Park JH, Cho B. Low albumin-to-globulin ratio associated with cancer incidence and mortal- ity in generally healthy adults. ANN ONCOL. 2014;25(11):2260\u20136. Received: 12 March 2023 / Accepted: 19 July 2023 17. Fitchett E, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, et al. Strengthening the reporting of Obser- vational Studies in Epidemiology for Newborn infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. LANCET INFECT DIS. 2016;16(10):e202\u201313. 18. Bozkaya Y, Erdem GU, Demirci NS, Yazici O, Ozdemir NY, Kostek O, Zengin N. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. CURR MED RES OPIN. 2019;35(2):275\u201382. References 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7\u201333. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. 3. Haseltine JM, Rimner A, Shepherd AF, Wu AJ, Gelblum DY, Shaverdian N, 2. 4. Gomez DR, Simone CN. Delivering safe and effective stereotactic body radia- tion therapy for patients with centrally located early stage non-small cell lung cancer. Chin Clin Oncol. 2020;9(3):39. Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. CANCER SCI. 2018;109(4):1207\u201319. 19. Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, Deng M. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135\u201348. 20. Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Shirabe K. Relationship between FDG uptake and Neutrophil/Lym- phocyte ratio in patients with invasive ductal breast Cancer. ANTICANCER RES. 2018;38(8):4927\u201331. 21. Liu Y, Yin Z, Lu P, Ma Y, Luo B, Xiang L, Zhang W, He Y, Liang X. Lung carcinoma cells secrete exosomal MALAT1 to inhibit dendritic cell phagocytosis, inflammatory response, Costimulatory Molecule expression and promote dendritic cell autophagy via AKT/mTOR pathway. Onco Targets Ther. 2020;13:10693\u2013705. 5. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with Advanced non\u2013small cell Lung Cancer. JAMA ONCOL. 2018;4(11):1569. Zhang H, Zhang B, Zhu K, Wu C, Gao L, Sun X, Liu C, Wang C. Preoperative albumin-to\u2010globulin ratio predicts survival in patients with non\u2010small\u2010cell lung cancer after surgery. J CELL PHYSIOL. 2019;234(3):2471\u20139. 6. 7. Gupta N, Sharma A, Sharma A. Emerging biomarkers"}], "doc_text": "the final manuscript. To our knowledge, we are the first to show that AGR may be a clinical indicator associated with OS for advanced NSCLC patients treated with anlotinib. Since AGR is a simple, inexpensive and easily available bio- marker, and is part of routinely administered laboratory tests, it is economically beneficial for its widespread clini- cal application. Despite the above-mentioned strengths, there are some limitations in our study. First, this study is a retrospective cohort study, and thus, it provides only weak evidence of associations between AGR and OS; it is hard to distinguish cause and effect. Second, the manifestations of possible selection bias, detection bias, and analysis bias might be confounded due to the nature of retrospective study. Third, as the absence of prior research in investigating the association between AGR and OS specifically in patients with ECOG PS score = 1 group, further investigations to understand the underlying mechanisms and determine if this relation- ship is consistent across different patient populations are Funding This work is funded by Xiamen Medical and Health Guidance Project (No. 3502Z20224ZD1085), grants from Shanghai science and technology innovation action plan (No. 21140902700), the National Natural Science Foundation of China (82170088), Natural Science Foundation of Fujian Province, China (2022J05330), and Major medical and health projects of Xiamen (No. 3502Z20204008). Data Availability The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Zhongshan hospital (Xiamen), Fudan university (B2022-067) and conducted in accordance with the principles of the Declaration of Helsinki. As it is a retrospective observational study, the ethics committee of Zhongshan hospital (Xiamen), Fudan university waived the requirement to obtain informed consent. Consent for publication Not applicable. Page 10 of 10 Competing interests The authors declare no competing interests. 12. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. AM J KIDNEY DIS. 1998;32(6 Suppl 4):118\u2013S125. Author details 1Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 2Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361000, Fujian, China 3Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China 4College of Computer and Data Science, Fuzhou University, Fuzhou 350108, Fujian, China 5Department of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361000, Fujian, China 6Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China 13. Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuett- fort VM, Karakiewicz PI, Roupr\u00eat M, Enikeev D, et al. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. WORLD J UROL. 2021;39(9):3345\u201352. 14. Xie H, Zhang Q, Ruan G, Ge Y, Hu C, Song M, Song C, Zhang X, Zhang X, Li X et al. Evaluation and validation of the Prognostic Value of serum albumin to globulin ratio in patients with Cancer Cachexia: results from a large Multi- center collaboration. FRONT ONCOL 2021, 11. 15. Guo X, Shao J, Zhai B, Zou Q, Yan J, Gu H, Wang G. Relationship and prognos- tic significance between preoperative serum albumin to globulin ratio and CT features of non-small cell lung cancer. EUR J RADIOL. 2020;128:109039. 16. Suh B, Park S, Shin DW, Yun JM, Keam B, Yang HK, Ahn E, Lee H, Park JH, Cho B. Low albumin-to-globulin ratio associated with cancer incidence and mortal- ity in generally healthy adults. ANN ONCOL. 2014;25(11):2260\u20136. Received: 12 March 2023 / Accepted: 19 July 2023 17. Fitchett E, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, Agarwal R, Ayede AI, Bhutta ZA, Black R, et al. Strengthening the reporting of Obser- vational Studies in Epidemiology for Newborn infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. LANCET INFECT DIS. 2016;16(10):e202\u201313. 18. Bozkaya Y, Erdem GU, Demirci NS, Yazici O, Ozdemir NY, Kostek O, Zengin N. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. CURR MED RES OPIN. 2019;35(2):275\u201382. References 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7\u201333. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. 3. Haseltine JM, Rimner A, Shepherd AF, Wu AJ, Gelblum DY, Shaverdian N, 2. 4. Gomez DR, Simone CN. Delivering safe and effective stereotactic body radia- tion therapy for patients with centrally located early stage non-small cell lung cancer. Chin Clin Oncol. 2020;9(3):39. Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. CANCER SCI. 2018;109(4):1207\u201319. 19. Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, Deng M. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135\u201348. 20. Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Shirabe K. Relationship between FDG uptake and Neutrophil/Lym- phocyte ratio in patients with invasive ductal breast Cancer. ANTICANCER RES. 2018;38(8):4927\u201331. 21. Liu Y, Yin Z, Lu P, Ma Y, Luo B, Xiang L, Zhang W, He Y, Liang X. Lung carcinoma cells secrete exosomal MALAT1 to inhibit dendritic cell phagocytosis, inflammatory response, Costimulatory Molecule expression and promote dendritic cell autophagy via AKT/mTOR pathway. Onco Targets Ther. 2020;13:10693\u2013705. 5. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with Advanced non\u2013small cell Lung Cancer. JAMA ONCOL. 2018;4(11):1569. Zhang H, Zhang B, Zhu K, Wu C, Gao L, Sun X, Liu C, Wang C. Preoperative albumin-to\u2010globulin ratio predicts survival in patients with non\u2010small\u2010cell lung cancer after surgery. J CELL PHYSIOL. 2019;234(3):2471\u20139. 6. 7. Gupta N, Sharma A, Sharma A. Emerging biomarkers"}